 |
|
Breast Cancer Trial Results
1. Paclitaxel Versus Docetaxel for Early Breast Cancer
(Posted: 04/30/2008) - Weekly treatment with the drug paclitaxel (Taxol®) in addition to standard chemotherapy proved most effective in extending overall survival among women with early-stage breast cancer, according to the April 17, 2008, New England Journal of Medicine.
2. Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial
(Posted: 03/26/2008) - Postmenopausal women taking the drug anastrozole (Arimidex®) to prevent a recurrence of breast cancer suffered more bone loss than women taking tamoxifen (Nolvadex®), even while anastrozole provided better protection against relapse, according to the March 1, 2008, Journal of Clinical Oncology.
3. Anthracyclines Improve Survival for HER2-Positive, But Not HER2-Negative, Breast Cancer
(Posted: 01/30/2008) - Chemotherapy with an anthracycline drug such as doxorubicin or epirubicin extends survival for women with HER2-positive, but not HER2-negative, breast cancer, according to a meta-analysis published in the Jan. 2, 2008, Journal of the National Cancer Institute.
4. Extra Fruits and Vegetables Don't Cut Risk of Further Breast Cancer: Results of the WHEL Study
(Posted: 09/26/2007) - In the WHEL study, a diet high in fruits, vegetables, and fiber and somewhat lower in fat did not protect early-stage breast cancer survivors from further breast cancer, nor did it help them live longer, according to the July 18, 2007, Journal of the American Medical Association.
5. Hypnosis Before Breast-Cancer Surgery Reduces Pain, Discomfort, and Cost
(Posted: 09/12/2007) - Women undergoing surgery for breast cancer who received hypnosis before entering the operating room required less anesthesia and pain medication during surgery, and reported less pain, nausea, fatigue, and discomfort after surgery than women who did not receive hypnosis, according to the Sept. 5, 2007, Journal of the National Cancer Institute.
1 2 3 4 Next >
|
|
|
